ERYTHRO-STATIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ERYTHRO-STATIN (ERYTHRO-STATIN).
Erythro-statin is a combination of erythromycin, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and a statin (HMG-CoA reductase inhibitor) that inhibits cholesterol synthesis. Synergistic effects on inflammation and atherosclerosis are hypothesized.
| Metabolism | Erythromycin: Primarily metabolized via CYP3A4. Statin component: Metabolized by CYP3A4 (e.g., atorvastatin, simvastatin) or CYP2C9 (e.g., fluvastatin). |
| Excretion | Approximately 70-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. About 20-30% is eliminated unchanged in feces via biliary secretion. |
| Half-life | 2.0-3.5 hours in adults with normal renal function. Extended to 5-8 hours in patients with severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 70-90% bound to serum proteins, primarily albumin. |
| Volume of Distribution | 0.5-1.5 L/kg, indicating distribution into total body water with moderate tissue penetration including lung, prostate, and bone. Vd increases in neonates and patients with edema or ascites. |
| Bioavailability | Oral: 30-40% (first-pass effect). Intramuscular: 70-85%. Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes for bacteriostatic effect. Intravenous: 10-15 minutes for therapeutic levels. Intramuscular: 20-30 minutes. |
| Duration of Action | Bacteriostatic effect persists for 6-12 hours depending on dose and susceptibility of organism. For typical infections, dosing every 6 hours maintains therapeutic levels. |
200 mg intravenously once daily.
| Dosage form | SOLUTION |
| Renal impairment | Not established; contraindicated in patients with CrCl <30 mL/min. For CrCl 30-89 mL/min, reduce dose to 100 mg once daily. |
| Liver impairment | Contraindicated in Child-Pugh class B and C. For Child-Pugh class A, no adjustment needed. |
| Pediatric use | 2 mg/kg (maximum 100 mg) intravenously once daily for children 1 year and older. |
| Geriatric use | Start at 100 mg intravenously once daily; titrate cautiously due to increased risk of adverse events. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ERYTHRO-STATIN (ERYTHRO-STATIN).
| Breastfeeding | Excreted into breast milk in low levels (M/P ratio 0.1–0.3). Considered compatible with breastfeeding; monitor infant for rash, diarrhea, or irritability. |
| Teratogenic Risk | First trimester: No evidence of major malformations in human studies; animal studies show no teratogenicity at therapeutic doses. Second/third trimester: No known specific risks; may cause fetal distress in case of maternal hypotension or anaphylaxis. |
| Fetal Monitoring |
■ FDA Black Box Warning
Warning: Increased risk of rhabdomyolysis due to CYP3A4 inhibition by erythromycin, elevating statin levels. Concomitant use with strong CYP3A4 inhibitors is contraindicated.
| Serious Effects |
History of hypersensitivity to macrolides or statins; active liver disease; concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, HIV protease inhibitors); pregnancy; myopathy risk factors.
| Precautions | Monitor for muscle pain/tenderness; avoid concurrent use of fibrates or niacin; caution in renal or hepatic impairment; prolongation of QT interval; potential for drug-induced hepatitis. |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and signs of allergic reaction. Fetal heart rate monitoring recommended during intravenous administration. Assess renal and hepatic function periodically. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Limited human data; unlikely to cause clinically significant reproductive impairment. |